lilly_building_with_american_flag_web

Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

pharmafile | March 13, 2019 | News story | Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma 

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at Phase 3 in combination with erlotinib, the company said, as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have activating EGFR mutations.

The data showed that the Cyramza combo achieved “statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment” compared to placebo plus erlotinib, meeting its primary endpoint of progression-free survival (PFS).

“Despite recent treatment advances in metastatic EGFR-mutated non-small cell lung cancer, prognosis remains poor and there is an ongoing need for additional first-line treatment options to help patients with this deadly disease,” Dr Maura Dickler, Vice President of Late Phase Development at Lilly Oncology. “We are excited about these results, which show Cyramza plus erlotinib significantly delayed disease progression in this patient population. The RELAY trial is another example of Lilly’s deep commitment to providing new treatment options to patients with lung cancer.”

Lilly said that it plans to launch efforts to secure regulatory approval around the world in mid-2019.

Matt Fellows

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …

Latest content